ÂÜÀòÂÒÂ×

Clemens Reinshagen has a strong background in translational research, particularly in the field of cancer therapy. With experience in both academia and industry, Clemens has demonstrated expertise in setting up laboratories, managing collaborations, and mentoring research teams. With a Doctor of Medicine degree from the University of Göttingen, Clemens' previous roles at Brigham and Women's Hospital and Massachusetts General Hospital have equipped him with valuable skills in cell-based therapies and CRISPR technology. Currently, as the Executive Director of Translational Research at PineTree Therapeutics Inc, Clemens continues to drive innovation in the development of bispecific antibodies for cancer therapy.